Vivalytic | SARS-CoV-2 Dual Target, Flu A/B and RSV
Vivalytic | SARS-CoV-2 Dual Target, Flu A/B and RSV


Vivalytic | SARS-CoV-2 Dual Target, Influenza A/B and RSV Rapid Test
–
Rapid differentiation between SARS-CoV-2, Flu A/B, and RSV
SARS-CoV-2 Dual Target, Influenza A/B and RSV Rapid Test
Patients infected with SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B) and/or Respiratory Syncytial Virus (RSV) have overlapping symptoms, but the approaches to patient management of infections caused by the viruses are different. SARS-CoV-2, Flu A/B, and RSV is a qualitative test for the rapid triage, and patient management to identify different viruses effectively providing pathogen-specific management and targeted treatment.
The combination of these tests additionally reduces costs whilst addressing the challenge of respiratory infections at the point of care, facilitating infection control and risk assessment.
Detection Method: Real-Time PCR
Result Time: < 1 hour
Sample Volume: 300 μl
Sample Type: Nasopharyngeal or Oropharyngeal Swab


Detectable Pathogens |
---|
SARS-CoV-2 (E gene and N gene) |
Influenza A and Influenza B |
Human Respiratory Syncytial Virus |
Vivalytic
Cartridge Based Testing Platform
The SARS-CoV-2 Dual Target, Influenza A/B and RSV rapid test on Vivalytic by Bosch, a point of care platform brought to the market by Randox Laboratories. The Vivalytic system is a fully automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy-to-use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.
Vivalytic Key Features:
- Cartridge based platform
- Fully automated
- Suitable for both non-laboratory & laboratory settings
- Small footprint device
- Rapid turnaround from sample entry to results

Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
The Randox Discovery, an exciting and unique diagnostic analyser which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High Design Quality.
Red Dot, which has become established as one of the top profile product design awards has roots dating back as far as 1955 and determines the best products created each year. Recognised as one of the largest global product competitions for innovation excellence, this sought-after seal for quality design attracts submissions from over 50 countries, across 49 different categories including medical devices and technology.
Dr Stuart Jackson, Randox Project Design Engineer, commented;
“Randox are delighted to have achieved the Red Dot design award, the culmination of five years of development and coordination of engineering design teams spanning two continents. The Discovery is a particularly unique innovation capable of automating Randox Biochip molecular diagnostics assays, from sample lysis and end-point PCR to multiplexing detection, with accessibility and ease-of-use at the forefront of the design.”
Dolmen were briefed by the Randox team to develop a creative and dynamic way to showcase the cutting-edge inner workings of the Discovery. Essentially, to turn the magic of the machine into a piece of theatre; not just a tool, but the centre of attention, a focal point for the lab that has excellent usability and accessibility throughout. Dolmen and Randox collaborated closely to deliver a revolutionary instrument that, amongst its many abilities, is a COVID-19 diagnostic analyser that is the first of its kind.
Chris Murphy, CEO and Design Director, Dolmen Design and Innovation, commented;
“We are delighted that our collaboration with Randox has delivered another Red Dot design award for our team. Randox as a team truly value the power of design and how it can deliver better outcomes for end users. It is also wonderful to see our designs delivering positive change at the frontline of the COVID pandemic. This project was hugely collaborative, and we look forward to more collaborations in the future.”


What makes the Discovery special is its ability to conduct the full testing process, inclusive of sample preparation techniques such as extraction, purification, amplification and detection, in one highly intelligent, fully integrated space. The preparation of COVID-19 samples before testing was once lengthy and time-consuming, requiring a separate, sterilized laboratory for each stage, but can now be conducted on-board and by the fully automated Discovery platform, allowing a single operator to run multiple molecular tests simultaneously.
Combining almost 40 years of diagnostics into one platform, bringing multiple labs into one the COVID-19 diagnostic analyser is the first of its kind to combine sample preparation techniques and Biochip Technology.
Professor Dr. Peter Zec, Red Dot CEO, commented;
“The winners of the Red Dot Award: Product Design 2021 were particularly impressive this year. The design of their products is excellent, in terms of both the aesthetic and the functionality. It’s not easy to prevail in such a strong field of competitors and to win over our jury. Consequently, I want to congratulate the laureates very sincerely on their success.”
For further information please email randoxpr@randox.com
Want to know more?
Contact us or visit our find out more about the Randox Discovery
Related Products
Randox Discovery
COVID 19 Product Overview
COVID 19 QPCR ASSAY
VIRAL RNA EXTRACTION KIT
Vivalytic | MG, MH, UP/UU Rapid Test



Vivalytic | MG, MH, UP/UU Rapid Test
–
Detection of Mycoplasma genitalium, Mycoplasma hominis & Ureaplasma parvum/ urealyticum
RT-PCR detection of common STI pathogenic bacterial species
Aiding in the diagnosis and containment of sexually transmitted infections (STIs) of symptomatic and asymptomatic individuals, the Vivalytic portfolio of tests has now expanded to complement current comprehensive screening.
The Mycoplasma genitalium (MG), Mycoplasma hominis (MH) & Ureaplasma parvum (UP)/urealyticum (UU) test guides appropriate treatment decisions at the earliest opportunity for improved patient management, prevention of transmission and supporting emerging macrolide resistance. MG, MH, UP/UU belong to the group of human pathogenic bacterial species associated with STIs even though particularly Ureaplasma ssp. are primarily considered as commensal organisms.
All four bacterial species can be detected simultaneously with the Vivalytic MG, MH, UP/UU test cartridge.
*Detail information on the determination of analytical performance can be found in instructions for use provided with the testing kit.
Detectable Bacteria |
---|
Mycoplasma genitalium |
Mycoplasma hominis |
Ureaplasma parvum/urealyticum |
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Vivalytic | SARS-CoV-2 Rapid Dual Target



Vivalytic | SARS-CoV-2 Dual Target Rapid Test
–
Detecting E & N gene sequence for SARS-CoV-2
SARS-CoV-2 Dual Target Detection
SARS-CoV-2 dual target is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay.
The SARS-CoV-2 dual target rapid test allows for detection of both the E-gene and N-gene sequence for SARS-CoV-2 with minimal workflow required, suitable for laboratory and non-laboratory settings. The SARS-CoV-2 dual target test also contains a Human and Internal PCR control for convenience.
In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first!*
*Detail information on the determination of analytical performance can be found in instructions for use provided with SARS-CoV-2 kit.
*Test Termination: If one of the target genes is clearly detected, the test can be terminated prematurely with the valid positive result.
Vivalytic Workflow
Detectable Virus |
---|
SARS-CoV-2 (E-gene and N-gene sequence) |
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
CDx & BioPharma Services
CDx & BioPharma Services
Offering a collaborative CDx partnership approach.
As an established IVD company, Randox Biosciences offers tailored development and testing solutions to support faster, more effective and safe development of new drugs.
We have a wide range of in-house capabilities, ranging from the selection and patenting of novel biomarkers; manufacture of bio reagents; production of single and multiplex RUO and IVD grade tests; quality control; provision of clinical laboratory services; regulatory expertise and worldwide distribution.
Pharmaceutical and biotech companies are increasingly investing in the research and development of new therapies to address the world’s growing need for earlier and more effective patient treatment.
Randox Biosciences is dedicated to the improvement of personalised diagnostic, prognostic, and predictive assays. We aim to help Pharma Biotechs and CROs move away from a “one treatment fits all” approach and help get a better understanding of the complexity and variability of diseases and increase efficacy of treatment. A key element to realizing the potential for personalized medicine is companion diagnostic (CDx) development. Randox have key expertise in all elements of CDx and diagnostic development and offer a fully flexible partnership to accommodate your needs, providing you with tailored protein & molecular assays.
Randox Biosciences can be your CDx and biomarker assay development partner from early phase trials through to drug launch, addressing all assay requirements in the process, including development of raw materials and assays, verification and validation studies, clinical trial sample analysis, regulatory submissions and co-commercialisation.


Complete CDx Partner Approach


Drug and Diagnostic Development Process Timeline
Randox Biosciences offers an extensive portfolio of over 900 products for a multitude of R&D applications manufactured under ISO13485 accreditation, including more than 500 monoclonal and polyclonal antibodies, 140 human recombinant proteins, as well as antibody fragments such as sdAbs and scFvs. In addition to our range of off-the-shelf raw materials, Randox can custom develop antibodies and proteins for use in new assays.
By using Randox antibodies, the raw material supply chain is controlled in-house which is highly beneficial for CDx development.
Randox offers a range of technologies and platforms for use in clinical trials, including our proprietary multiplex biochip technology that can be used in early exploratory biomarker stages and can be brought through to IVD/CDx grade. Biochip from high throughput to point of care technologies.
With comprehensive Original Equipment Manufacturing (OEM) capabilities, Randox can develop assays on any platform to ensure global reach.
All assays intended for IVD or CDx grade are developed under full design control and ISO13485 accreditation, and we have expertise in a wide range of disease areas and assay formats.
Randox have ISO17025, ISO15189 and GCP accredited laboratories located throughout the UK and Ireland, with US laboratories being mobilised in 2022 and 2023. Our laboratories can be utilised to meet your clinical trial and post approval sample analysis needs. We also have a strong global network with 3rd party laboratories to ensure your clinical trial requirements are met across the world.
Randox performs in depth multi lot verifications following CLSI guidelines to ensure full performance requirements are met and to support regulatory submissions and approvals. We will validate assay performance and reproducibility across multiple sites.
Highly experienced regulatory teams inhouse at Randox can prepare IVD/CDx submissions and applications for approval, thus, providing full regulatory support to help get your drug to the market as quickly as possible.
Development and regulatory teams will work hand-in-hand throughout the whole process and in collaboration with the Pharma partner, to ensure a timely submission while also keeping in line with country specific requirements.
We currently have 954 licenses across the globe and over 3800 licensed products to date, with continuous expansion ongoing including progression to IVDR regulation.


Randox endeavors to start commercialization planning early on in development to ensure all market access requirements are addressed, providing both pre and post-launch support with laboratory, clinician, patient and KOL engagement and can also conduct sample analysis at our clinical laboratories.
We have strong global laboratory and distribution networks, in-house sales and marketing teams, with operations and partners in over 145 countries.
We have capabilities in manufacturing customised sample collection kits and offer CDx specific proficiency testing programmes.
We can provide pre- and post-launch support with laboratory, clinician, patient and KOL engagement and can also conduct sample analysis at our clinical laboratories.
Randox Platforms
Randox response to the Public Accounts Committee (PAC) report, ‘Government’s contracts with Randox Laboratories Ltd’



27th July 2022: Randox response to the Public Accounts Committee (PAC) report, ‘Government’s contracts with Randox Laboratories Ltd’
A spokesperson for Randox said:
“The PAC report is deeply flawed and wrong in assumptions it makes and the conclusions it draws about Randox.
“As the UK’s largest diagnostic company, with four decades of experience, over 2,000 professional staff on hand at the start of the pandemic and more than £350m of prior investment in diagnostic and engineering innovation, Randox was uniquely situated to respond to the national need when COVID-19 emerged in early 2020.
“In supporting the UK’s urgent requirement for coronavirus testing Randox reacted with speed, efficiency and flexibility in delivering value. The company developed and built, in record time, the UK’s largest COVID-19 laboratories and testing services. It provided the Department of Health and Social Care with a PCR testing capacity at the time of greatest need, rising from 300 tests per day to 120,000 per day by January 2021.
“Altogether Randox processed over 25 million samples for UK’s National Testing Programme and in support of international travel for business and personal reasons. This played a crucial role in keeping vital elements of the UK economy functioning during lockdowns.
“In adapting to rapidly changing DHSC and Department of Transport requirements, Randox delivered unique value to the government, the national economy and to individuals.
“At no stage, either during its deliberations or in its preparation of this report, did the PAC make any contact whatsoever with Randox. Consequently many elements of its report relating to Randox are false, based as they are, on wrong and unchecked assumptions about the company. For that reason, they and any publications arising from them are the subject of a legal complaint.”
“The issues the report raises around internal DHSC record keeping are clearly a matter for DHSC”
For all media enquiries, please contact Ian Monk on ian@ianmonk.com or +44 7970 026072 / + 44 203 011 1933
Randox in the media
Latest News
FAQs
SARS-CoV-2 Antigen Test EI & MultiSTAT


SARS-CoV-2 Antigen Test
–
Quantitative measurement of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swab
Simultaneous detection of SARS-CoV-2 nucleocapsid protein
Randox have developed an Antigen test for SARS-CoV-2 for the quantitative measurement of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swab samples. Designed to aid in the identification of individuals with SARS-CoV-2, the Randox antigen test provides a timely and accurate diagnosis imperative to limit virus spread and to provide appropriate treatment to patients.
Viral antigens are only expressed when the virus is actively replicating, thus making antigen tests such as the Evidence Investigator SARS-CoV-2 antigen test clinically valuable for identification of acute/early infection.
Ordering Information
Description | Cat Code |
---|---|
54 Biochip Investigator Kit for SARS-CoV-2 Antigen | EV4451/A |
Control Kit for SARS-CoV-2 Antigen Test | EV4451/B |
Available Platforms
Evidence Investigator
Estimated turnaround time: 2.5 hours
Medium throughput (54 samples)
Batch testing
Suitable for laboratory setting
Comprehensive immunoassay and molecular test menu available


Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
SARS-CoV-2 Rapid Test
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Response to release of specified minutes, notes and correspondence relating to Government contracts awarded to Randox



4th February 2022: Response to release of specified minutes, notes and correspondence relating to Government contracts awarded to Randox
A spokesperson for Randox said:
“It is clear from these papers that Randox contracts were awarded in full compliance with government procedures and protocols in place at a time of the emerging pandemic.
“The awarding of the contracts reflected Randox’s extensive diagnostics capabilities within the UK and 40 years of experience in that field. As Secretary of State, Sajid Javid says in his statement, the service Randox provided was integral to the rapid building, from scratch, of the largest ever testing industry in UK history.
“Randox’s laboratories expanded rapidly in order to operate at scale and were the first laboratory to report over 100,000 PCR results in a day. It is clear from these papers that the company has delivered a vital and core part of the UK’s testing capacity.
“Randox remains proud of its performance and delivery of Covid 19 testing throughout the pandemic. To date Randox has reported almost 24 million PCR results and has played a key role in both keeping people safe and sustaining vital national infrastructure.
“Unlike other laboratories Randox was able from the outset to provide whole-system capabilities to deliver the tests. Both the World Health Organisation and the UK government agreed this capability was crucial to combating the pandemic.”
For all media enquiries, please contact Ian Monk on ian@ianmonk.com or +44 7970 026072 / + 44 203 011 1933
Randox in the media
Latest News
FAQs
2 years on…since the development of the Randox COVID-19 Biochip
Wednesday 02 February 2022: 2 years since the Randox COVID-19 Biochip
February 2022 marks 2 years since the development of the Randox COVID-19 Biochip.
In February 2020, based on almost four decades of experience in diagnostic R&D, including the development of a CE marked panel of tests for fifteen respiratory viruses, as well as tests for SARS and MERS, Randox recognised the threat from COVID-19 and quickly developed a test to accurately identify the virus.
And a lot has happened since then…
Randox’s capability was recognised by the UK government and since March 2020 Randox has been contracted to provide COVID-19 testing support to the UK’s Pillar 2 National Testing Programme. The company immediately pivoted to move from a 9-5 business to a 24|7 operation.
Through the enormous effort and commitment of its staff Randox has (at the time of writing) processed more than 23 million gold-standard PCR tests for the National Testing Programme and for international travel – providing a reliable service to enable COVID-safe travel which facilitates personal, family and business engagements and activities during the pandemic.
Demonstrating its commitment to helping people live their lives as easily and normally as possible, and to enhance accessibility to travel testing, the company partnered with major airlines including British Airways, Easyjet, Ryanair, Wizz Air, Cathay Pacific, and Jet2, travel providers such as TUI, and travel agents including the DNATA Travel Group, to provide discounted travel tests. By investing in testing capacity, logistic capabilities, and the introduction of a dedicated Customer Support team, Randox could make greater efficiencies that allowed it to reduce the price of PCR testing and become the most competitive service in the UK and Ireland.
During the 2020 Olympic Games, Randox got Team GB safely to the starting line in Tokyo by providing the Olympians with its premium COVID-19 testing, a service which it also provided for the ParalympicsGB athletes. A number of other sporting organisations opted to make Randox their COVID-19 testing provider of choice for their players and supporting staff, including the Irish Football Association, the US Men’s National Soccer Team, and Premiership Rugby, to ensure a COVID-safe training environment. Using Randox diagnostic technologies, companies like Norbrook Laboratories and Northern Ireland Screen were able to implement a staff screening programme that demonstrated a high standard of duty of care to their employees.
As and when required, Randox rapidly established new customer-focused services catered to the needs of the ever-changing travel testing guidelines. In May 2021, for example, Randox launched a ‘test to return’ service for UK holidaymakers returning home from Portugal and requiring predeparture tests before their return flight. In a first for the industry, passengers were able to take their PCR kit to Portugal and return their sample to one of Randox’s partner labs in the Algarve, before Randox flew the samples back to its labs in the UK for testing.


The company also provides tests for COVID-19 antibodies, as well as lateral flow testing services, where such tests satisfy international travel requirements, and has developed an innovative phone app to securely process and verify customer identification and results in just 15 minutes.
Randox has amongst the very largest laboratories in Europe and since the start of the pandemic has built, equipped and staffed 80,000 sq ft of PCR testing facilities, in Northern Ireland, Manchester and Greater London, and 50,000 sq ft of supporting logistic and engineering space. Randox has opened a number of mobile testing labs as well as almost 30 travel clinics, for COVID-19 testing appointments and over-the-counter home testing kit purchases. Walk-through and drive-through test centres have opened across a number of key airport locations, some in partnership with renowned travel services provider Collinson.
Randox is the only testing provider in the UK within this reporting period to have reported over 100,000 PCR results in a single day. Turnaround times for test results are rigorously monitored to meet the needs of both Government and private customers.
The company has more than doubled its workforce since 2020 and has developed a robust and comprehensive nationwide logistics network for the timely distribution and return of sample collection kits and samples. In collaboration with reputable partners including Morrisons supermarkets, Wells Pharmacies, Roadchef and PayPoint, Randox has established almost 200 PCR sample dropboxes and over 1500 click and collect sites, with the aim of improving customer accessibility and simplifying the process of COVID-19 testing requirements.
By responding rapidly, dynamically and cost-effectively to an ever-changing environment, with updates to travel testing requirements often being made at short notice, Randox has played an important role in managing the effects of the pandemic in both the UK and Ireland, facilitating safe social and economic activity, including international travel.
For further information on Covid testing services please contact the Randox Covid Customer Support team on 028 9434 3005.
For press enquiries please contact Amy Millar in the Randox PR team: randoxpr@randox.com
Want to know more?
Contact us or visit Randox Health.
Related COVID-19 Products and Services
HOME TEST
ANTIBODY TEST
TEST TO RELEASE
LABORATORY TOOLS
Randox provides Team GB’s COVID testing for Beijing Winter Olympic Games
Tuesday 01 February 2022
Gold standard testing for Great Britain’s Olympians: Randox provides Team GB’s COVID-19 testing for Beijing Winter Olympic Games
As part of the two-year partnership between Randox and The British Olympic Association, the Team GB Olympians competing in the Olympic Winter Games 2022 have used Randox COVID-19 tests to ensure they touch down in Beijing free of COVID and have the best possibility opportunity to compete without the fear of being ruled out on health grounds.
The ‘stop the virus’ logistics drive mirrors a similar and highly successful regime which ensured that Team GB landed in Japan for the 2020 Olympic Games COVID-free, and that no athlete was forced to withdraw in Tokyo because of infection or close contact with someone who had tested positive.
Despite fears that the virus could impact Team GB’s Olympic hopes, the rigorous testing programme put in place helped UK sporting stars to rack up 54 medals – their best-ever performance at an overseas Games bar the 67 medals won in Rio in 2016.
To provide its gold-standard PCR testing services, Randox created a bespoke dashboard for Team GB to register its samples, which will be taken by the Team GB Clinical Team and then transported to the company’s laboratories which are located in Manchester, Greater London and Northern Ireland.
Randox is testing a delegation of 200 Olympians, coaches and support staff in order to meet China’s testing requirements and thereby minimising possible transmission of the virus in Beijing. Randox is providing each member of Team GB with four rounds of pre-departure tests and can offer rapid same-day testing on the day of flying as an extra precaution.
At the time of the announcement of the partnership between Randox and the British Olympic Association, in June 2021, Randox Managing Director, Dr Peter FitzGerald, said:
“We are delighted to be supporting Team GB by helping them get safely to the starting line in Tokyo with our premium Covid-19 testing services, the provision of which has been a major focus of ours since the outbreak of the pandemic. Over the last year, we have been investing significantly in our customer service and testing capacity, which means Randox can now process over 500,000 tests per day, making it the largest laboratory in Europe, and to date has processed over 13 (now 23) million tests. For this reason, our Olympians and anyone else who needs to travel internationally can rest assured that they will receive timely results.”
British Olympic Association CEO, Andy Anson, said:
“This is a fantastic and vital partnership for Team GB ahead of Tokyo 2020 and Beijing 2022. We have committed to our hosts in Japan and the IOC to ensure that our delegation is fully vaccinated and are also ensuring we have enhanced Covid testing in place. Randox’s pedigree in this area gives us great confidence that we are providing athletes with the best possible medical support around Covid testing and that they get to the start line safely ready to compete successfully for the biggest moment of their sporting careers.”
Randox, with almost 40 years of international diagnostics experience, has been at the forefront of COVID-19 testing since the outset of the pandemic. With proven testing capability and well-established logistics and customer support services, Randox are strongly placed to allow international travellers to travel with confidence.


Pictured with a Randox COVID-19 Predeparture Test is English freestyle skier Katie Summerhayes
For further information on Covid testing services please contact the Randox Covid Customer Support team on 028 9434 3005.
For press enquiries please contact Amy Millar in the Randox PR team: randoxpr@randox.com
Want to know more?
Contact us or visit Randox Health.